Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients

#1105

Introduction: There is a growing need to identify PRRT-responders on an early time point during therapy.

Aim(s): Can pre-therapeutic uptake on 68Ga-DOTATOC PET predict outcome of PRRT?

Materials and methods: Forty-four NET patients were treated with 3 or 4cycles of 1.85GBq/m²/cycle 90Y-DOTATOC up to a maximal kidney biological effective dose of 37Gy.A 68Ga-DOTATOC-PET/CT was performed before and 40weeks after the first cycle of PRRT(PRRT1). Response was assessed by CT,40weeks after PRRT1;progression free survival(PFS) was based on follow up CT and clinical information.Three to six target lesions were prospectively chosen on PETbaseline and median SUVmax was assessed.The relationship between median SUVmax-baseline and PFS, Ki67-index and tumor grade was examined and ROC-analysis was performed among others.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Van Binnebeek S

Authors: Van Binnebeek S, Vanbilloen B, Baete K, Bogaerts K, Koole M,

Keywords: PET, response, PRRT,